Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: insulin degludec Clear all
Recruiting Phase 2 Interventional

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

NCT07215312
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3938577, Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Tucson, Arizona • Spring Valley, California • Tustin, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

NCT02500706
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Tucson, Arizona • Concord, California • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Jun 7, 2026, 4:39 AM EDT
Terminated Not applicable Interventional

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

NCT03001323
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Degludec, Standard long-acting
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01835431
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

NCT02298192
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Hamilton, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

NCT01046110
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, sitagliptin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Huntsville, Alabama • Concord, California • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

NCT01959529
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
7,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
267
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

NCT01680341
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01068678
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Northridge, California • Palm Springs, California • Paramount, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

NCT01814137
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

NCT01135992
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
27
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

NCT01125553
View directory record Official record
Conditions
Diabetes, Healthy
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

NCT01364428
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Huntsville, Alabama • Goodyear, Arizona • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 in Participants With Type 1 Diabetes

NCT03214367
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Mobile, Alabama • Concord, California • Escondido, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Concord, California • Los Angeles, California • Montclair, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Insulin Pump to Multiple Daily Injection Transition Clinical Trial

NCT03987191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiple daily ijnection using Insulin Degludec and Insulin Aspart
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

IDegLira HIGH Trial

NCT03737240
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
IDegLira, Insulin Degludec (U-100), Insulin Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Not applicable Interventional Results available

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

NCT01569841
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin

NCT04770532
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin Icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
38
States / cities
Buena Park, California • Encino, California • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01513473
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes

NCT01045707
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
41
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Concord, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Not applicable Interventional

Insulin Degludec Titration Using Mobile Insulin Dosing System

NCT03091712
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glooko Mobile Insulin Dosing System(MIDS)
Device
Lead sponsor
Glooko
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Jun 7, 2026, 4:39 AM EDT